RYTHMOL 300 MG — DIN 00603716
PROPAFENONE HYDROCHLORIDE : 300 MG · BGP PHARMA ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is RYTHMOL?
RYTHMOL 300 MG contains PROPAFENONE HYDROCHLORIDE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 00603716, held by BGP PHARMA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Jun-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RYTHMOL used for?
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained VT) and symptomatic ventricular arrhythmias of sufficient severity. Benefit must outweigh proarrhythmic risks.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Propafenone cost around the world?
Propafenone is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 20 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 13 | EUR███.██ |
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
40 pack listings across 15 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Propafenone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Propafenone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Propafenone, across 19 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 4 | 2 | MYL-PROPAFENONE, MYLAN-PROPAFENONE | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO-PROPAFENONE | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | RYTHMOL | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 0 | PMS-PROPAFENONE | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | PROPAFENONE-150, PROPAFENONE-300 | No marketed DIN |
| SANIS HEALTH INC | 2 | 0 | PROPAFENONE | No marketed DIN |
| NU-PHARM INC | 1 | 0 | NU-PROPAFENONE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100 tablets. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated), typically 15-30°C for such forms. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Propafenone |
|---|---|
| ATC code | C01BC03 |
| AHFS class | 24:04.04.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00603716 |
|---|---|
| DIN (unpadded, as printed on some documents) | 603716 |
| Brand name | RYTHMOL |
| Generic / active ingredient | PROPAFENONE HYDROCHLORIDE : 300 MG |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Prescription |
| ATC code | C01BC03 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01BC |
| Current status | MARKETED |
| Status date | 17-Jun-2016 |
| Original market date | 1988-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initial: 150 mg q8h (450 mg/day). May increase every 3-4 days to 300 mg q12h (600 mg/day), max 300 mg q8h (900 mg/day). Administer with food; swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity, Brugada Syndrome, MI within 3 months, severe/uncontrolled CHF, cardiogenic shock, conduction disorders without pacemaker, severe bradycardia, severe hypotension, bronchospasm.
Warnings and precautions
Serious Warning: No antiarrhythmic shown to reduce sudden death in asymptomatic patients. May cause proarrhythmia, worsen CHF, or cause agranulocytosis. May unmask Brugada Syndrome.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-PROPAFENONE | 300 MG | TABLET | APOTEX INC | MARKETED | 02243325 |
| APO-PROPAFENONE | 150 MG | TABLET | APOTEX INC | MARKETED | 02243324 |
| MYLAN-PROPAFENONE | 150 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02457172 |
| MYLAN-PROPAFENONE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02457164 |
| RYTHMOL | 150 MG | TABLET | BGP PHARMA ULC | MARKETED | 00603708 |
| MYL-PROPAFENONE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02245373 |
| MYL-PROPAFENONE | 150 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02245372 |
| NU-PROPAFENONE | 150 MG | TABLET | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | 02249480 |
| PMS-PROPAFENONE | 300 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02243728 |
| PMS-PROPAFENONE | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02243727 |
2 · Same class — other molecules in ATC C01BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Flecainide | AG-FLECAINIDE · APO-FLECAINIDE · AURO-FLECAINIDE · FLECAINIDE · +4 more | 16 | 10 | Yes |
| Propafenone | APO-PROPAFENONE · MYL-PROPAFENONE · MYLAN-PROPAFENONE · NU-PROPAFENONE · +5 more | 19 | 6 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01BD | Amiodarone · Bretylium Tosilate · Dronedarone · Ibutilide | 43 | 14 |
| C01BB | Lidocaine · Mexiletine · Tocainide | 22 | 8 |
| C01BA | Disopyramide · Procainamide · Quinidine | 44 | 1 |
| C01BG | Vernakalant | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.